LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS

LCCC 0412：I 期卡铂和 ABRAXANE 用于实体瘤患者

• 批准号: 7625597
• 负责人: Thomas Stinchcombe
• 金额: $ 1.43万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625597
• 关键词: Abraxane; Carboplatin; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Patients; Phase; Purpose; Research; Research Personnel; Resources; Solid Neoplasm; Source; United States National Institutes of Health; Week

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine highest dose of Abraxane that can be safely given with carboplatin when Abraxane is given once a week or every 3 weeks.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是确定当每周一次或每 3 周给予 Abraxane 时，与卡铂一起安全给予的 Abraxane 最高剂量。